Pharming, Santarus submit angioedema drug for FDA approval

04/18/2013 | Pharmaceutical Business Review Online

Pharming Group and Santarus have filed a biologics license application with the FDA for approval to use Ruconest, a recombinant human C1 esterase inhibitor, as a treatment for acute angioedema attacks in people with hereditary angioedema. Santarus holds the right to market the drug in North America.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX